Exelixis, Inc. http://www.alacrastore.com/company-snapshot/Exelixis_Inc-2102786 Friday, July 25, 2008 6:33:50 PM 2102786 Exelixis, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/BW-0001-26843966newstex/BW-0001-26843966xml Jul. ##, #### (Business Wire) -- Exelixis, Inc. (Nasdaq:EXEL) will release its second quarter #### financial results on Tuesday, August #, ####, after the markets close. The announcement will be followed by a live webcast at #:##...04000000040180000401600004016048040160187/22/2008 5:16:49 PM180000001800800018004000Business WireBW-0001-26843966EXELIXIS INCEXELNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-26282248newstex/PRN-0005-26282248xml SOUTH SAN FRANCISCO, Calif., Jun. ##, #### (PRNewswire-FirstCall delivered by Newstex) -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and GlaxoSmithKline, Inc. (NYSE: GSK) will bring their six-year collaboration to...0700000007005000110000001100200004000000040020000400200604016000040160130701400007014012070140086/27/2008 7:16:02 AM180000001802200018015000PR Newswire USPRN-0005-26282248EXELIXIS INCGLAXOSMITHKLINE PLCGEORGE A SCANGOSEXELGSKNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T1870680ccbn/T1870680norm...Good day, ladies and gentlemen, and welcome to the Deerfield Committed Funding conference call. At this time all participants are in listen-only mode. We will conduct a question-and-answer session toward the end of this conference. (OPERATOR INSTRUCTIONS) As a reminder this conference is being recorded for replay purposes. I will now turn the call over to Mr. Charles Butler. Please proceed. ... 6/5/2008 11:04:33 AMExelixis106.0000FinalExelixis Business Update TranscriptEXEL5:00am PTTranscriptT1870680Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1870680ccbn/B1870680norm...On ##/##/##, EXEL signed a $###m credit line facility with Deerfield. Under the terms of the agreement, Deerfield has committed $###m that can be drawn by EXEL in $##m increments over the next ## months. ... 6/5/2008 10:04:00 AMExelixis54.0000EditedExelixis Business Update SummaryEXEL5:00am PTBriefB1870680Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25775251newstex/PRN-0005-25775251xml SOUTH SAN FRANCISCO, Calif., Jun. #, #### (PRNewswire-FirstCall delivered by Newstex) -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company has entered into an agreement with Deerfield Management, a leading healthcare investment...11000000110020000400000004002000040020011300000013010000130100056/5/2008 7:21:25 AM180000001802200018008000PR Newswire USPRN-0005-25775251EXELIXIS INCFRANK NULL KARBEGEORGE A SCANGOSEXELNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1828960ccbn/B1828960norm...XL###, which is an inhibitor of PI# kinase and mTOR, will have Phase # data, and both of those compounds will be presented in oral presentations. ... 5/6/2008 10:06:00 PMExelixis54.0000EditedQ1 2008 Exelixis Earnings Conference Call SummaryEXEL2:00pm PTBriefB1828960Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1828960ccbn/T1828960norm...Good day, ladies and gentlemen, welcome to the first quarter #### Exelixis earnings conference call. My name is Amanda, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's call, Mr. Charles Butler, the Senior Director of Investor Relations. Please proceed, sir. ... 5/6/2008 6:06:00 PMExelixis54.0000FinalQ1 2008 Exelixis Earnings Conference Call TranscriptEXEL2:00pm PTTranscriptT1828960Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/newstex/PRN-0005-25057822newstex/PRN-0005-25057822xml SOUTH SAN FRANCISCO, Calif., May #, May #, #### (PR Newswire delivered by Newstex) -- SOUTH SAN FRANCISCO, Calif., May # /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter...07000000070050000400000004002000040020060401600004016018040160010701400007014012070140080100000001011000010110011300000013010000130100055/6/2008 5:19:23 PM1800000018004000190000001900100019001005PR Newswire USPRN-0005-25057822BRISTOL MYERS SQUIBB COBRISTOL-MYERS SQUIBB COMPANY $2 CONVERTIBLEEXELIXIS INCGENENTECH INCGEORGE A SCANGOSBMYBMY PRDNAEXELNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/PRN-0005-24834371newstex/PRN-0005-24834371xml SOUTH SAN FRANCISCO, Calif., April ##, Apr. ##, #### (PR Newswire delivered by Newstex) -- SOUTH SAN FRANCISCO, Calif., April ## /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) will release its first quarter #### financial...04000000040180000401600004016048040160184/28/2008 7:19:29 AM180000001800800018004000190000001900100019001005PR Newswire USPRN-0005-24834371EXELIXIS INCEXELNewsNewstexhttp://www.alacrastore.com/storecontent/bir/738823bir/738823normExelixis Inc.Genomica Corp.Exelixis Pharmaceuticals Inc.Agritope Inc.United StatesServices: Provider of genomics and model system genetics services for the pharmaceutical, diagnostic and other industries.873154171017EHEXEL2/29/2008 6:16:00 AM738823Company Profiles & FinancialsGale Company Profileshttp://www.alacrastore.com/storecontent/ccbn/B1761024ccbn/B1761024normQ# #### Exelixis Earnings Conference Call2/14/2008 9:05:49 PMExelixis106.0000EditedQ4 2007 Exelixis Earnings Conference Call SummaryEXEL2:00pm PTBriefB1761024Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1761024ccbn/T1761024normQ# #### Exelixis Earnings Conference Call2/14/2008 7:07:39 PMExelixis106.0000FinalQ4 2007 Exelixis Earnings Conference Call TranscriptEXEL2:00pm PTTranscriptT1761024Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1750106ccbn/T1750106normExelixis at Wachovia Healthcare Conference2/1/2008 11:08:00 AMExelixis54.0000FinalExelixis at Wachovia Healthcare Conference TranscriptEXEL9:30am ETTranscriptT1750106Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1733027ccbn/T1733027norm1/14/2008 12:06:00 PMExelixis54.0000FinalExelixis at JPMorgan Healthcare Conference TranscriptEXEL7:30am PT... - JPMorgan - Senior Biotech Analyst Good morning. My name is Cory Kazimov. I'm a Senior Biotech Analyst here at JPMorgan, and the first company to present to us here today is Exelixis, a biopharmaceutical company focused on the discovery and development of potential new therapies for cancer and metabolic disorders. Exelixis has evolved into a development stage company with a dozen drug candidates currently in clinical development, three of which are expected to proceed into pivotal programs this year. Presenting for Exelixis is George Scangos, President and CEO, and please note there will be a breakout session following this presentation in the Olympic Room. So with that, let me turn it over to George. ... TranscriptT1733027Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1706385ccbn/T1706385norm12/31/2007 5:21:33 PMExelixis54.0000FinalExelixis Investor Briefing Meeting TranscriptEXEL8:00pm ET...And I think we're making excellent progress with other compounds. XL###, our selective MEK inhibitor, that's in Phase I right now. And then our two PI#K inhibitors, XL### and ###. And again, the trend we hope to continue by having this early POC data helping us prioritize our assets so that we can invest properly and push the best compounds forward as quickly as possible. So tonight we'll talk about XL###, which is a potent and highly selective JAK# inhibitor. I think selectivity is one aspect of this program that we focused on very early, based upon the biology of the different systems and the role that the different JAKs play in cytokine and growth factor signaling. It was very important for us to maximize the selectivity between JAK# and the other JAK numbers, JAK#, JAK# and JAK#, but also to really profile our compounds and optimize our compounds to maximize our selectivity across a wide range of kinases. And I think you'll see tonight in Peter's discovery profile that we've been able... TranscriptT1706385Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1694993ccbn/T1694993norm12/31/2007 5:21:18 PMExelixis54.0000FinalExelixis Third Annual R&D Day TranscriptEXEL10:00am ET... - Exelixis, Inc. - President and CEO Okay. Let us get started. First, let me welcome everybody, thank you all for coming. This is an event obviously which takes a lot of preparation for those of us in the Company, but it is one which we also look forward to, because it is the -- it is really the single opportunity we have to lay out our R&D portfolio and our strategy in a little more detail and certainly in more detail than we get to do at a half hour investor presentation or some conference or even in one-on-one meetings. So, our goal for today is really to lay out where we are, where we are going in the strategy and how we are going to get there. Before we start, I have to read a statement to you. So, before we get started I would like to note that during our presentation today, we will be making certain statements that are forward-looking, including without limitation, those relating to the future development and potential efficacy of our compounds, the timing for initiation of clinical... TranscriptT1694993Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/B1676002ccbn/B1676002norm11/5/2007 9:06:00 PMExelixis54.0000EditedQ3 2007 Exelixis Earnings Conference Call SummaryEXEL5:00pm ET...Reported Phase I data for Co.'s second inhibitor of MET, XL### and two inhibitors of the PI# kinase pathway XL### and XL### and several other compounds. ... BriefB1676002Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1676002ccbn/T1676002norm11/5/2007 6:06:00 PMExelixis54.0000FinalQ3 2007 Exelixis Earnings Conference Call TranscriptEXEL5:00pm ET...Good day, ladies and gentlemen. Thank you, very much, for your patience and welcome to the third quarter #### Exelixis earnings conference call. My name is Bill and I will be your conference coordinator for today. At this time, all participants are in a listen-only mode. We will be conducting a question-and-answer session towards the end of today's conference. (OPERATOR INSTRUCTIONS) As a reminder, today's conference is being recorded for replay purposes. I would now like to turn the call over to our host for today's conference, Mr. Charles Butler, Director of Investor Relations. Please proceed, sir. ... TranscriptT1676002Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1657533ccbn/T1657533norm10/11/2007 12:06:00 PMExelixis54.0000FinalExelixis at Biotechnology Industry Organization Investor Forum TranscriptEXEL2:45pm PT...[The next] company is Exelixis from south San Francisco. And presenting for the Company is the President of Research and Development, Michael Morrissey. ... TranscriptT1657533Credit & Investment ResearchThomson Street Eventshttp://www.alacrastore.com/storecontent/ccbn/T1635605ccbn/T1635605norm9/6/2007 9:06:00 AMExelixis54.0000FinalExelixis IASLC 2007 Analyst and Investor Briefing TranscriptEXEL8:00am ET...Good day, ladies and gentlemen, and welcome to the Exelixis conference call to update XL### Phase II clinical data. (OPERATOR INSTRUCTIONS) I would now like to turn the presentation over to the Director of Investor Relations, Mr. Charles Butler. Please proceed, sir. ... TranscriptT1635605Credit & Investment ResearchThomson Street Events